Boston Therapeutics has a new tablet PAZ320 designed to reduce a person's sugar intake by 40%. CEO Dr. David Platt believes the tablet will eventually be approved for non-diabetic patients looking to cut back on the copious amounts of sugar prevalent in many processed foods. The company also makes an intravenous drug that will help diabetic foot ulcers heal more quickly.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

[video] New Tablet From Boston Therapeutics Reduces Sugar Intake for Diabetics